Tokyo Tape
Sign in
← Nipro

Quarterly report · Q1

8086.TEDINET S100OZ7P
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥127.9bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥494.8bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥118.0bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥3.0bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥5.5bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥7.3bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥27.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥5.2bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥9.0bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥5.3bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥5.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.3bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥5.7bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥3.5bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥947.6bnat 2022-06-30Cons.Assets
Total assets¥930.3bnat 2022-03-31Cons.Assets
Total assets¥874.8bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥730.3bnat 2022-06-30Cons.Liabilities
Total liabilities¥730.5bnat 2022-03-31Cons.Liabilities
Net assets / equity¥217.3bnat 2022-06-30Cons.Net assets
Net assets / equity¥199.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥185.9bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥84.7bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥95.3bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥32.352022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.52021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥20.242021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥28.662022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥77.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
Equity ratio21.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio19.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio19.8%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥1.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥154m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥855m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥211m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥9.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥9.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥7.1bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥99.3bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥97.7bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.5bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥23.2bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥17.9bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥5.3bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥407m
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-06-30¥13.7bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-06-30¥12.2bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.5bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.0bn
—segment totalrevenue2022-04-01 → 2022-06-30¥136.2bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥127.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥8.4bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥9.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥137.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥127.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥9.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥10.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥693m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥153m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥540m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30¥145m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥8.8bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥8.8bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥5.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue2021-04-01 → 2021-06-30¥92.2bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2021-04-01 → 2021-06-30¥90.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1.5bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2021-04-01 → 2021-06-30¥9.5bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue2021-04-01 → 2021-06-30¥21.5bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue external2021-04-01 → 2021-06-30¥16.4bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentsegment profit2021-04-01 → 2021-06-30¥587m
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue2021-04-01 → 2021-06-30¥12.4bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue external2021-04-01 → 2021-06-30¥10.8bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1.6bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentsegment profit2021-04-01 → 2021-06-30¥844m
—segment totalrevenue2021-04-01 → 2021-06-30¥126.1bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥117.8bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥8.2bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥10.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥126.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥118.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥8.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥11.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 442
ItemContextValueUnit
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember8760000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-8760000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember92161000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02688-000MedicineRelatedReportableSegmentsMember21484000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02688-000PharmaPackagingReportableSegmentMember12422000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember126068000000JPY
Net salesPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember693000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember126761000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-8760000000JPY
Net salesPrior1YTDDuration118001000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember9506000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02688-000MedicineRelatedReportableSegmentsMember587000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E02688-000PharmaPackagingReportableSegmentMember844000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember10938000000JPY
Operating incomePrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember145000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember11083000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-5566000000JPY
Operating incomePrior1YTDDuration5517000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember97653000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02688-000MedicineRelatedReportableSegmentsMember17870000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E02688-000PharmaPackagingReportableSegmentMember12214000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember127738000000JPY
Revenues from external customersCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember154000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember127892000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration127892000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember1628000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02688-000MedicineRelatedReportableSegmentsMember5300000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E02688-000PharmaPackagingReportableSegmentMember1510000000JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember8440000000JPY
Transactions with other segmentsCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember855000000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember9296000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-9296000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember99282000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E02688-000MedicineRelatedReportableSegmentsMember23170000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E02688-000PharmaPackagingReportableSegmentMember13725000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember136178000000JPY
Net salesCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember1010000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember137188000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-9296000000JPY
Net salesCurrentYTDDuration127892000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember8461000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E02688-000MedicineRelatedReportableSegmentsMember407000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E02688-000PharmaPackagingReportableSegmentMember1012000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember9882000000JPY
Operating incomeCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember211000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember10094000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-7140000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass